Entero Therapeutics's total assets for Q3 2025 were $135.37M, an increase of 59.15% from the previous quarter. ENTO total liabilities were $45.81M for the fiscal quarter, a 54.36% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.